Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype
Putting the theory of personalised medicine into practice
Personalised cancer medicine and research: Today’s best practice
Too few women being offered breast-conserving treatment?
Molecular stratification of breast cancer: reaching the clinic
Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)
Effects of lapatinib and trastuzumab on progression free survival
Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer
Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer
Highlights and goals of IMPAKT 2012
Endocrine therapy and endocrine resistant breast cancer
Targeting DNA damage response and repair excluding PARP for triple negative breast cancer